Patients may not have received any other investigational agents within 4 weeks of study entry
Patients may not be receiving any other investigational agents
Patients receiving any other investigational agents
Patients receiving any other investigational agents
Patients may not be planning to receive any other investigational agents
Receiving any other investigational agent
Receiving any other investigational agent
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents are not eligible
Patients who are receiving any other anticancer or investigational agents
Patients should not be receiving any other investigational agents
Patients receiving any other investigational agents are ineligible
Patients who are actively receiving any other investigational agents
Patients should not be receiving any other investigational agents
Patients should not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
TUMOR BIOPSY SEQUENCING: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
TREATMENT: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chair
Patients who are receiving any other investigational agents or who have received pomalidomide in the past
Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll 4 weeks after completion of prior agent)
Patients who are receiving any other investigational agents
Participants who received any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents (replacement doses of steroids for adrenal insufficiency are permitted or treatment with prednisone =< 5 mg/day); receipt of investigational agents within the 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational or approved agents for hepatitis C, are also exclusionary
Patients who are receiving any other investigational therapy
Patients who are receiving any other therapeutic investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents are ineligible
Receiving any other investigational agents =< 28 days prior to registration
Patients who are receiving any other investigational agents
Concurrent administration of any other investigational agents
Patients who are receiving any other investigational agent(s)
Patients may not be receiving any other investigational agents while on study
Patients receiving any other investigational agents are ineligible
Participants who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptable
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients must not currently be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of 4 weeks is required
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents are ineligible
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents while on study treatment
Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
Any other investigational agents within the past 4 weeks
Patients who are receiving any other investigational agents
Patient is receiving another investigational agent for the treatment of cancer
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients should not have received any other investigational agents within the past 4 weeks
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients must not be receiving or planning to receive any other investigational agents
Patients who are receiving any other biologic, cytotoxic or investigational agents
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents for cancer
Patients receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients must not be receiving any other investigational anti-cancer agents while on study
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within five half-lives of the compound or 3 months, whichever is greater
Participants should not have received any other investigational agents nor have participated in an investigational trial within the past 4 weeks
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents are ineligible
Patients who are receiving any other investigational agent
Patients receiving any other investigational agents are ineligible
